HIKALNSEHikal Limited· PharmaceuticalsHighNegative
Announced Wed, 7 Jan · 17:59 IST

The Exchange has sought clarification from Hikal Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.

Regulatory & Legal

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The NSE has asked Hikal Limited to clarify discrepancies found in the XBRL-formatted financial results submitted for the quarter ended September 30, 2025, under Regulation 33 of SEBI's Listing Regulations. The exchange has flagged issues in the XBRL filing and is awaiting the company's response. No details on the nature of the discrepancies have been shared publicly yet. This appears to be a routine compliance query rather than a serious enforcement action.

Likely market impact

Minor procedural matter that usually has limited impact on stock price. Shareholders should watch for the company's response, as repeated non-compliance could invite further regulatory scrutiny, but this is unlikely to materially affect business or valuations in the near term.